专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

81. 发明授权

US5387746A Pulmonary hydrophobic surfactant-associated protein of 6,000 daltons molecular weight and multimers thereof 失效
标题翻译： 6,000道尔顿分子量的肺疏水性表面活性剂相关蛋白及其多聚体
公开(公告)号：US5387746A
公开(公告)日：1995-02-07
申请号：US975202
申请日：1992-11-12
申请人： Jeffrey A. Whitsett
发明人： Jeffrey A. Whitsett
IPC分类号： A61K38/00 , A61K38/04 , C07K14/785 , C07K16/18 , G01N33/68 , A61K37/02 , C07K7/10
CPC分类号： G01N33/6884 , A61K38/04 , C07K14/785 , C07K16/18 , Y10S530/848
摘要： A novel hydrophobic surfactant-associated protein mixture, i.e., a SAP-6 proteins, has been isolated from pulmonary animal tissue. A small, novel pulmonary hydrophobic surfactant-associated SAP-6-Val protein having a molecular weight of about 6,000 daltons as determined by SDS-PAGE and about 3,500-4,000 daltons as determined by tricine-SDS-PAGE has been further isolated from the SAP-6 protein mixture. The amino acid residue compositions of the SAP-6-Val protein for human and bovine have been determined and disclosed. When a SAP-6-Val protein is combined with phospholipids, it enhances the surfactant-like activity of the phospholipids in lungs of animals and, therefore, uniquely imparts to the mixture significant pulmonary biophysical activity. Such a mixture results in enhanced adsorption of the phospholipids with properties similar to that of natural pulmonary surfactant material. SAP-6-Val proteins in combination with phospholipids is highly useful for replacing or supplementing natural pulmonary surfactant material for reducing or maintaining normal surface tension in lungs, and especially in lungs of patients suffering from hyaline membrane disease, HMD, or other syndromes associated with the lack or insufficient amounts of natural pulmonary surfactant material. A mixture of a SAP-6-Val protein and phospholipids may be administered as an aerosol spray or in aqueous normal saline with or without calcium chloride for treating or preventing HMD and other surfactant deficiency states. Also disclosed are methods of isolating the noncanine SAP-6-Val proteins from the SAP-6 proteins isolated from animal tissue.
摘要翻译：从肺动物组织中分离出一种新的疏水表面活性剂相关蛋白混合物，即SAP-6蛋白。通过SDS-PAGE测定分子量为约6,000道尔顿，通过tricine-SDS-PAGE测定的约3,500-4,000道尔顿的小型新型疏水表面活性剂相关SAP-6-Val蛋白质已从SAP中进一步分离 -6蛋白混合物。人和牛的SAP-6-Val蛋白的氨基酸残基组成已被确定和公开。当SAP-6-Val蛋白与磷脂组合时，它增强动物肺中磷脂的表面活性样活性，因此独特地赋予混合物显着的肺生物物理活性。这种混合物导致磷脂的吸附性能与天然肺表面活性剂材料相似。 SAP-6-Val蛋白与磷脂组合是非常有用的替代或补充天然肺表面活性剂材料，以减少或保持肺部正常的表面张力，特别是在患有透明膜疾病，HMD或与其相关的其他综合征患者的肺部天然肺表面活性物质的量不足或不足。 SAP-6-Val蛋白和磷脂的混合物可以作为气溶胶喷雾剂或含有或不含氯化钙的水性生理盐水施用，用于治疗或预防HMD和其它表面活性剂缺乏状态。还公开了从动物组织分离的SAP-6蛋白质分离非蔗糖SAP-6-Val蛋白质的方法。

82. 发明授权

US5378807A .gamma.-poly(glutamic acid) esters 失效
标题翻译： γ-聚（谷氨酸）酯
公开(公告)号：US5378807A
公开(公告)日：1995-01-03
申请号：US832255
申请日：1992-02-07
申请人： Richard A. Gross , Stephen P. McCarthy , Devang T. Shah
发明人： Richard A. Gross , Stephen P. McCarthy , Devang T. Shah
IPC分类号： B60R25/10 , B62J3/00 , G08B3/10 , C07K7/10
CPC分类号： B60R25/1001 , B62J3/00 , G08B3/10
摘要： A method is disclosed for significantly diminishing the rate of degradation of naturally-produced .gamma.-PGA in a .gamma.-PGA-producing cell culture. Also, a method is disclosed for significantly decreasing the water solubility coefficient of naturally-produced .gamma.-PGA by forming derivatives of .gamma.-PGA. In addition, a polymer solution is disclosed which includes a polysaccharide component and a .gamma.-PGA component.
摘要翻译：公开了一种显着降低在产生γ-PGA的细胞培养物中天然产生的γ-PGA降解速率的方法。此外，公开了通过形成γ-PGA的衍生物来显着降低天然产生的γ-PGA的水溶性系数的方法。此外，公开了一种聚合物溶液，其包括多糖组分和γ-PGA组分。

83. 发明授权

US5374618A Calcitonin peptides, and gene related pharmaceutical compositions 失效
标题翻译：降钙素肽和基因相关的药物组合物
公开(公告)号：US5374618A
公开(公告)日：1994-12-20
申请号：US705423
申请日：1985-02-14
申请人： Roger K. Craig , Mark R. Edbrooke
发明人： Roger K. Craig , Mark R. Edbrooke
IPC分类号： A61K35/74 , A61K38/00 , A61K38/23 , A61K39/00 , A61K39/395 , A61P9/08 , A61P9/12 , A61P43/00 , C07K1/113 , C07K1/20 , C07K5/10 , C07K7/06 , C07K7/08 , C07K14/435 , C07K14/575 , C07K14/585 , C07K16/00 , C07K19/00 , C12N1/21 , C12N15/09 , C12P21/02 , C12Q1/68 , C12R1/19 , G01N33/50 , G01N33/531 , G01N33/58 , A61K37/02 , C07K7/10
CPC分类号： C07K14/585 , C07K14/57527 , A61K38/00
摘要： This invention relates to human gene related peptide pharmaceutical compositions containing the peptide and the method of treating hypertension with said pharmaceutical composition.
摘要翻译： PCT No.PCT / GB84 / 00210 Sec。 371日期1985年2月14日 102（e）日期1985年2月14日PCT申请日1984年6月15日PCT公布。第WO85 / 00043号公报 1985年1月3日。本发明涉及含有肽的人类基因相关肽药物组合物和用所述药物组合物治疗高血压的方法。

84. 发明授权

US5340718A Method for assaying a human muscular dystrophy protein 失效
标题翻译：测定人类肌营养不良蛋白的方法
公开(公告)号：US5340718A
公开(公告)日：1994-08-23
申请号：US9392
申请日：1993-01-27
申请人： Tsuneo Ishiguro , Chikahiko Eguchi
发明人： Tsuneo Ishiguro , Chikahiko Eguchi
IPC分类号： C07K14/47 , G01N33/68 , G01N33/53 , C07K7/10 , C07K15/00 , C07K15/28
CPC分类号： C07K14/4708 , G01N33/6893 , G01N2800/2878 , G01N2800/2885
摘要： Methods and polypeptides for assaying human proteins associated with Duchenne muscular dystrophy, are disclosed.
摘要翻译：公开了用于测定与杜烯肌营养不良相关的人类蛋白质的方法和多肽。

85. 发明授权

US5328899A NPY peptide analogs 失效
标题翻译： NPY肽类似物
公开(公告)号：US5328899A
公开(公告)日：1994-07-12
申请号：US882923
申请日：1992-05-12
申请人： Jaroslav H. Boublik , Jean E. F. Rivier , Marvin R. Brown , Neal A. Scott
发明人： Jaroslav H. Boublik , Jean E. F. Rivier , Marvin R. Brown , Neal A. Scott
IPC分类号： A61K38/00 , C07K14/575 , A61K37/02 , C07K7/08 , C07K7/10
CPC分类号： C07K14/57545 , A61K38/00
摘要： Human Neuropeptide Y (NPY) has the formula: H-Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro- Ala-Glu-Asp-Met-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile- Thr-Arg-Gln-Arg -Tyr-NH.sub.2. Porcine and rat NPY have the same sequence except for Leu instead of Met in the 17-position. Porcine PYY is homologous having 11 different residues. NPY analogs and N-terminally-shortened fragments, e.g. NPY(18-36), which contain one or more specific D-isomer substitutions for the naturally occurring residues (as well as pharmaceutically acceptable salts thereof), dispersed in a pharmaceutically acceptable liquid or solid carrier, can be administered to mammals, including humans, to substantially lower blood pressure over an extended period of time or to counteract hypertension.
摘要翻译：人神经肽Y（NPY）具有下式：H-Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala-Glu-Asp-Met-Ala-Arg- Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr-NH2。猪和大鼠NPY具有相同的序列，除了Leu而不是17位的Met。猪PYY具有11个不同残基的同源物。 NPY类似物和N-末端缩短的片段，例如对于分散在药学上可接受的液体或固体载体中的天然存在的残基（以及其药学上可接受的盐）含有一个或多个特异性D-异构体取代的NPY（18-36）可以施用于包括人在内的哺乳动物，以在更长的时间内大幅降低血压或抵抗高血压。

86. 发明授权

US5294605A Amphiphilic peptide compositions and analogues thereof 失效
标题翻译：两亲肽组合物及其类似物
公开(公告)号：US5294605A
公开(公告)日：1994-03-15
申请号：US725331
申请日：1991-07-08
申请人： Richard A. Houghten , Sylvie Blondelle
发明人： Richard A. Houghten , Sylvie Blondelle
IPC分类号： A61K38/00 , C07K7/08 , C07K14/46 , A61K37/02 , C07K7/10
CPC分类号： C07K14/46 , C07K7/08 , A61K38/00
摘要： A process for inhibiting growth of a target cell comprising administering to a host or to a target cell or virus a biologically active peptide which includes one of the following basic structures; R.sub.1 -R.sub.1 -R.sub.2 -R.sub.1 -R.sub.1 -R.sub.2 -R.sub.2 -R.sub.1 -R.sub.1 -R.sub.2 -R.sub.2 -R.sub.1 -R.sub.2 -R.sub.2 ; R.sub.2 -R.sub.1 -R.sub.1 -R.sub.2 -R.sub.2 -R.sub.1 -R.sub.2 -R.sub.2 -R.sub.1 -R.sub.1 -R.sub.2 -R.sub.2 -R.sub.1 -R.sub.1 ; or R.sub.1 -R.sub.2 -R.sub.1 -R.sub.1 -R.sub.2 -R.sub.2 -R.sub.1 -R.sub.1 -R.sub.2 -R.sub.2 -R.sub.1 -R.sub.2 -R.sub.2 -R.sub.1 -R.sub.1 -R.sub.2 -R.sub.2 -R.sub.1, wherein R.sub.1 is a hydrophobic amino acid, and R.sub.2 is a basic hydrophilic or neutral hydrophilic amino acid. A preferred peptide is of the structural formula:(SEQ ID NO:3).Substitution and deletion analogues of this peptide can be prepared that have increased biological activity. Such peptides can be employed as pharmaceuticals.
摘要翻译：一种抑制靶细胞生长的方法，包括向宿主或靶细胞或病毒施用包括以下基本结构之一的生物活性肽; R1-R1-R2-R1-R1-R2-R2-R1-R1-R2-R2-R1-R2-R2; R2-R1-R1-R2-R2-R1-R2-R2-R1-R1-R2-R2-R1-R1; 或R1-R2-R1-R1-R2-R2-R1-R1-R2-R2-R1-R2-R2-R1-R1-R2-R2-R1，其中R1是疏水性氨基酸，R2是碱性亲水或中性亲水氨基酸。优选的肽具有以下结构式：（SEQ ID NO：3）。可以制备具有增加的生物活性的该肽的取代和缺失类似物。这样的肽可以用作药物。

87. 发明授权

US5281581A Treatment of insulin resistance 失效
标题翻译：治疗胰岛素抵抗
公开(公告)号：US5281581A
公开(公告)日：1994-01-25
申请号：US901602
申请日：1992-06-19
申请人： Garth J. S. Cooper , Howard Greene, Jr.
发明人： Garth J. S. Cooper , Howard Greene, Jr.
IPC分类号： A61K38/00 , A61P3/10 , C07K14/575 , C07K16/26 , A61K37/02 , C07K7/08 , C07K7/10
CPC分类号： C07K16/26 , C07K14/575 , A61K38/00 , Y10S514/866
摘要： Compounds and methods for blocking the effects of diabetes-associated peptide, or "amylin", a hormone found in the amyloid masses of Type 2 diabetics. This putative hormone has been discovered to function both to inhibit insulin secretion and to inhibit glycogen synthesis. Regulation is accomplished by blocking the binding of amylin or amylin agonists, including calcitonin gene related peptide (CGRP], or biologically active sub-peptides thereof. Inhibitors include substituted peptides or sub-peptides of amylin or CGRP, cross-linked amylin and amylin agonists, synthetic amylin, anti-amylin receptor antibodies and anti-idiotype antibodies, and antibodies directed to amylin and amylin agonist active sites. Other antagonists include organic compounds which can be screened and assayed for anti-amylin effects by disclosed methods.
摘要翻译：用于阻断糖尿病相关肽或“胰岛淀粉样多肽”的作用的化合物和方法，其是在2型糖尿病患者的淀粉样蛋白质中发现的激素。已经发现这种推定的激素既能抑制胰岛素分泌又抑制糖原合成。通过阻断胰岛淀粉样多肽或胰岛淀粉样多肽激动剂（包括降钙素基因相关肽（CGRP））或其生物活性亚肽的结合来完成调节。抑制剂包括取代的肽或胰岛淀粉样多肽或CGRP的亚肽，交联的胰岛淀粉样多肽和胰岛淀粉样多肽激动剂，合成的胰岛淀粉样多肽，抗胰岛淀粉样多肽受体抗体和抗独特型抗体，以及针对胰岛淀粉样多肽和胰岛淀粉样多肽激动剂活性位点的抗体。其他拮抗剂包括可以通过公开的方法筛选和测定抗胰淀素效应的有机化合物。

88. 发明授权

US5278144A Antithrombosis agents 失效
标题翻译：抗血栓形成剂
公开(公告)号：US5278144A
公开(公告)日：1994-01-11
申请号：US578646
申请日：1990-09-04
申请人： David Wolf
发明人： David Wolf
IPC分类号： A61K38/43 , A61K38/00 , A61P7/02 , C07K14/00 , C07K14/475 , C07K14/745 , C07K14/81 , C12N5/10 , C12N9/64 , C12N15/09 , C12P21/02 , C07K7/10 , A61K37/02
CPC分类号： C12N9/647 , C07K14/745 , C12N9/6432 , C12Y304/21006 , A61K38/00
摘要： Analogs of Factor Xa (Factor Xai) which are inactive as proteases in the prothrombinase reaction are useful in treatment of diseases characterized by thrombosis. These antithrombotic agents can be conveniently prepared using recombinant techniques.
摘要翻译：在凝血酶原酶反应中作为蛋白酶失活的因子Xa（因子Xai）的类似物可用于治疗以血栓形成为特征的疾病。这些抗血栓形成剂可以使用重组技术方便地制备。

89. 发明授权

US5272252A Synthetic lung surfactant having antioxidant properties 失效
标题翻译：具有抗氧化性能的合成肺表面活性剂
公开(公告)号：US5272252A
公开(公告)日：1993-12-21
申请号：US789918
申请日：1991-11-04
申请人： Larry R. McLean , Marquerite H. Payne
发明人： Larry R. McLean , Marquerite H. Payne
IPC分类号： A61K38/00 , A61P11/16 , C07K1/113 , C07K7/06 , C07K7/08 , C07K14/785 , A61K37/02 , C07K7/10
CPC分类号： C07K14/785 , A61K38/00
摘要： Synthetic pulmonary surfactants having antioxidant properties consisting of a complex of a polypeptide, with an antioxidant moiety, having an alpha-helical structure and a lipid consisting of one or more of the lipids associated with natural pulmonary surfactant were prepared. These surfactants are useful in the treatment of respiratory distress syndrome.
摘要翻译：制备具有由具有α-螺旋结构的多肽与抗氧化剂部分的复合物和由与天然肺表面活性剂相关的一种或多种脂质组成的脂质组成的抗氧化性质的合成肺表面活性剂。这些表面活性剂可用于治疗呼吸窘迫综合征。

90. 发明授权

US5268358A PDGF receptor blocking peptides 失效
标题翻译： PDGF受体阻断肽
公开(公告)号：US5268358A
公开(公告)日：1993-12-07
申请号：US701350
申请日：1991-05-06
申请人： Larry J. Fretto
发明人： Larry J. Fretto
IPC分类号： A61K38/00 , C07K14/71 , C07K7/06 , A61K37/02 , C07K7/08 , C07K7/10
CPC分类号： C07K14/71 , A61K38/00
摘要： Methods and compositions are provided for treating several acute disease states associated with smooth muscle cell proliferation as well as the chronic process of atherogenesis utilizing oligopeptides corresponding to regions of the PDGF receptor protein. The oligopeptides can be used to block PDGF binding and activation for numerous applications, and can serve as immunogens to raise receptor-specific antibodies.
摘要翻译：提供了用于治疗与平滑肌细胞增殖相关的几种急性疾病状态的方法和组合物，以及使用对应于PDGF受体蛋白质区域的寡肽的动脉粥样硬化形成的慢性过程。寡肽可以用于阻断多种应用的PDGF结合和活化，并且可以作为提供受体特异性抗体的免疫原。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式